Export

EN
FR
Sofosbuvir
Essential medicine status
Section:
6. Anti-infective medicines 6.4. Antiviral medicines 6.4.4. Antihepatitis medicines 6.4.4.2. Medicines for hepatitis C 6.4.4.2.1. Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
ATC codes: J05AP08
EMLc
Indication
Chronic hepatitis C ICD11 code: 1E91.1
INN
Sofosbuvir
Medicine type
Chemical agent
List type
Core (EML)
(EMLc)
Additional notes
Pangenotypic when used in combination with daclatasvir or ravidasvir.
Formulations
Oral > Solid > tablet: 200 mg ; 400 mg
EML status history
First added in 2015 (TRS 994)
Changed in 2019 (TRS 1021)
Changed in 2021 (TRS 1035)
Changed in 2023 (TRS 1049)
Sex
All
Age
Also recommended for children
Therapeutic alternatives
Medicines within the same pharmacological class can be used
Therapeutic alternatives limitations
Pangenotypic direct-acting antiviral combinations
Therapeutic alternatives limitations for EMLc
Pangenotypic direct-acting antiviral combinations
Patent information
Main patent is active in several jurisdictions. For more information on specific patents and license status for developing countries visit www.MedsPal.org
Wikipedia
Sofosbuvir
DrugBank
Sofosbuvir
Summary of evidence and Expert Committee recommendations
The note associated with the listing of sofosbuvir was updated following the recommendation to include ravidasvir on the EML.